PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number 10/627,372 Filing Date July 24, 2003 First Named Inventor Harrihar A. PERSHADSINGH Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned Attorney Docket Number 421842000400

(Martina Placid)

Total Numbe	r of Pages in This Submiss	ion 28 + 110 Refs.	Attorney Docket Numb	421842000400		
	EN	CLOSURES	(Check all that app	oly)		
Fee Transr	nittal Form	Drawing(s)		After Allowance Communication to Group		
Fee /	Attached	Licensing-r	elated Papers	Appeal Communication to Board of Appeals and Interferences		
Amendmer	nt/Reply	Petition		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
After	Final		Convert to a Application	Proprietary Information		
Affida	avits/declaration(s)		torney, Revocation Correspondence Address	Status Letter		
Extension of	of Time Request	Terminal D	isclaimer	X Other Enclosure(s) (please identify below):		
Express At	pandonment Request	Request for Refund		1. Form PTO-1449 (12 pages in duplicate)		
x Information (3 pages)	n Disclosure Statement	CD, Number	er of CD(s)	References (110) Return receipt postcard		
Certified Control Document(opy of Priority (s)					
	to Missing Parts/ Application	Remarks				
	oonse to Missing Parts or 37 CFR 1.52 or 1.53					
	. 07 31 11 11.32 31 1.33					
	SIGNATU	JRE OF APPLIC	CANT, ATTORNEY, OF	RAGENT		
Firm or Individual name	MORRISON & FOER			25226		
individual flame	Shantanu Basu - 43,	310		······································		
Signature	Hanlun	Day				
Date	November 21, 2003					
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.						

Signature: Martina Placed

pa-841125

Dated: November 21, 2003



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 21, 2003.

Mutina Placed

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Harrihar A. PERSHADSINGH

Serial No.: 10

10/627,372

Filing Date:

July 24, 2003

For:

NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION,

EDEMA OR CONGESTIVE HEART

FAILURE

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. §1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references numbered 1 through 109 are not submitted. Copies of foreign patent documents and non-patent

literature are submitted herewith in accordance with 37 C.F.R. § 1.98 (a)(2). The Examiner is requested to make these documents of record.

	This Inf	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Before	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114.
\boxtimes	Withi	n three months of the application filing date or before mailing of a first Office
	Action	n on the merits; accordingly, no fee or separate requirements are required.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Action	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
•		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 421842000400. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated:

November 21, 2003

Respectfully submitted,

J

Shantanu Basu

Registration No. 43,318

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5995 Facsimile: (650) 494-0792

Form	P	ΓO-	1449	
------	---	-----	------	--

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

NOV 2 4 2003

(Use several sheets if necessary)

	Dilect 1 Of 12		
Docket Number 421842000400	Application Number 10/627,372		
Applicant			
Harrihar A. PE	RSHADSINGH		
Filing Date July 24, 2003 Group Art Unit Not Yet Assigned			
Mailing Date November 21, 2003			

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/15/2000	RE 36,575	Meguro et al.			
	2.	07/07/1992	5,128,356	Naka et al.			
	3.	11/10/1992	5,162,326	Naka et al.			
	4.	03/23/1993	5,196,444	Naka et al.			
	5.	09/07/1993	5,243,054	Naka et al.			
-	6.	10/05/1993	5,250,554	Naka et al.			
	7.	02/08/1994	5,284,661	Morimoto et al.			
	8.	07/12/1994	5,328,919	Naka et al.			
	9.	10/11/1994	5,354,766	Naka et al.			
	10.	02/14/1995	5,389,641	Naka et al.			
- T	11.	03/28/1995	5,401,764	Naka et al.	10 - 3		
	12.	10/31/1995	5,463,073	Takehiko et al.			
	13.	03/05/1996	5,496,835	Kubo et al.			
	14.	03/19/1996	5,500,427	Kubo et al.			,
	15.	04/09/1996	5,506,245	Regnier et al.			
	16.	07/30/1996	5,541,229	Narr et al.			
	17.	10/15/1996	5,565,469	Mihm et al.			
	18.	12/10/1996	5,583,141	Naka et al.			
	19.	12/24/1996	5,587,393	Narr et al.			· ·
	20.	01/07/1997	5,591,762	Hauel et al.			
	21.	01/14/1997	5,594,003	Hauel et al.			
	22.	02/11/1997	5,602,127	Hauel et al.			
	23.	03/25/1997	5,614,519	Hauel et al.			
	24.	06/17/1997	5,639,773	Kubo et al.			
	25.	09/02/1997	5,663,186	Nelson et al.			
	26.	09/02/1997	5,663,187	Nelson et al.			
	27.	11/04/1997	5,684,029	Narr et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Application Number 10/627,372 Form PTO-1449 Docket Number 421842000400 **Applicant** NEORMATION DISCLOSURE CITATION IN AN APPLICATION Harrihar A. PERSHADSINGH Filing Date July 24, 2003 (Use several sheets if necessary) Group Art Unit Not Yet Assigned NDV 2 4 2003 Mailing Date November 21, 2003 RADEMARKO 28. 12/02/1997 5,693,651 Nomura et al. 29. 12/30/1997 5,703,110 Naka et al. 30. 01/06/1998 5,705,517 Naka et al. 31. 04/07/1998 5,736,555 Naka et al. 32. 04/21/1998 5,741,803 Pool et al. 09/01/1998 Lohray et al. 5,801,173 33. 34. 09/22/1998 5,811,439 Ogawa et al. 35. 10/06/1998 Giungo 5,817,075 10/20/1998 Kurtz et al. 5,824,694 36. 37. 10/27/1998 Haigh et al. 5,827,865 38. 11/10/1998 5,834,501 Fujita et al. Yan 12/01/1998 5,843,172 39. Pershadsingh et al. 40. 12/01/1998 5,843,970 Doebber et al. 41. 12/08/1998 5,847,008 01/12/1999 Adams et al. 5,859,051 42. 01/26/1999 43. 5,864,043 Narr et al. 44. 02/09/1999 Giungo et al. 5,868,728 45. Haigh et al. 02/09/1999 5,869,495 03/16/1999 Naka et al. 46. 5,883,111 47. 03/23/1999 5,885,997 Lohray et al. Fujita et al. 48. 03/23/1999 5,886,014 49. 03/30/1999 5,889,025 Lohray et al. 50. 03/30/1999 5,889,032 Lohray et al. 51. 05/11/1999 5,902,726 Kliewer et al. 52. 06/08/1999 5,910,592 Pool et al. 53. 07/06/1999 5,919,782 Lohray et al. Kallam et al. 07/20/1999 54. 5,925,656 Sohda et al. 55. 08/03/1999 5,932,601 08/17/1999 5,939,442 56. Evans et al. 57. 09/14/1999 Ikeda et al. 5,952,356 DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 820933

Docket Number 421842000400 Application Number 10/627,372 Form PTO-1449 **Applicant** INFORMATION DISCLOSURE CITATION Harrihar A. PERSHADSINGH IN AN APPLICATION (Use several sheets if necessary) Filing Date July 24, 2003 Group Art Unit Not Yet Assigned Mailing Date November 21, 2003 RADENA 58. 09/14/1999 5,952,509 Saito et al. 59. 09/28/1999 5,958,942 Takatani et al. 60. 09/28/1999 5,958,961 Inada et al. 61. 10/05/1999 5,962,470 Fujita et al. 5,962,491 Naka et al. 62. 10/05/1999 63. 10/12/1999 5,965,584 Ikeda et al. 64. 10/19/1999 5,968,589 Murakami 65. 10/26/1999 5,972,959 Yanagisawa et al. 66. 10/26/1999 Sohda et al. 5,972,970 67. 11/02/1999 Fujita et al. 5,977,365 68. 11/16/1999 5,985,884 Lohray et al. 69. 11/23/1999 Yano et al. 5,990,139 70. 12/21/1999 6,004,989 Naka et al. 71. 12/28/1999 6,008,237 Sahoo et al. 72. 01/04/2000 6,011,031 Lohray et al. 73. 01/04/2000 Lohray et al. 6,011,036 6,020,382 Doebber et al. 74. 02/01/2000 75. 02/08/2000 6,022,897 Evans et al. 76. 02/22/2000 6,028,088 Pershadsingh et al. Matsui et al. 77. 07/11/2000 6,087,384 07/11/2000 Pershadsingh et al. 78. 6,087,385 07/18/2000 6,090,836 79. Adams et al. 80. 07/18/2000 6,090,839 Adams et al. 81. 08/08/2000 6,100,252 Naka et al. 82. 08/08/2000 6,100,403 Saito et al. 83. 08/15/2000 6,103,742 Ikeda et al. 84. 09/05/2000 6,113,907 Khwaja et al. 85. 09/12/2000 6,117,893 Fujita et al. Fujiwara et al. 86. 11/21/2000 6,150,371 Adams et al. 87. 12/12/2000 6,160,000 DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

88. 03/13/2001 6,200,995 De La 89. 05/08/2001 6,228,874 Inada 90. 05/15/2001 6,232,334 Naka 91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	Filing Date July 24, 2003 Mailing Date November 21, 200 Brouse-Elwood et al. et al.		SHADSINGH Group Art Unit N	lot Yet Assigne	ed	
88. 03/13/2001 6,200,995 De La 89. 05/08/2001 6,228,874 Inada 90. 05/15/2001 6,232,334 Naka 91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,355,808 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	Filing Date July 24, 2003 Mailing Date November 21, 200 Brouse-Elwood et al. et al. et al.			lot Yet Assigne	ed	
88. 03/13/2001 6,200,995 De La 89. 05/08/2001 6,228,874 Inada 90. 05/15/2001 6,232,334 Naka 91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,355,808 Preiff 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	Mailing Date November 21, 200 a Brouse-Elwood et al. et al. et al.	03				
88. 03/13/2001 6,200,995 De La 89. 05/08/2001 6,228,874 Inada 90. 05/15/2001 6,232,334 Naka 91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	et al.					
88. 03/13/2001 6,200,995 De La 89. 05/08/2001 6,228,874 Inada 90. 05/15/2001 6,232,334 Naka 91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,355,808 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	et al.		T			
89. 05/08/2001 6,228,874 Inada 90. 05/15/2001 6,232,334 Naka 91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	et al.		1			
90. 05/15/2001 6,232,334 Naka 91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	et al.					
91. 12/11/2001 6,329,415 Cirillo 92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng						
92. 12/25/2001 6,333,325 Cirillo 93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persha 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persha 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng						
93. 02/19/2002 6,348,481 Inada 94. 03/05/2002 6,353,011 Persham 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persham 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	o et'al.		-,			
94. 03/05/2002 6,353,011 Persham 95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persham 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng) 		
95. 03/12/2002 6,355,808 Naka 96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persham 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	adsingh					
96. 03/19/2002 6,358,945 Breitf 97. 04/09/2002 6,369,098 Persham 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng				· · · · · · · · · · · · · · · · · · ·		
97. 04/09/2002 6,369,098 Persham 98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	felder et al.				· · · · · · · · · · · · · · · · · · ·	
98. 04/16/2002 6,372,773 Regar 99. 07/02/2002 6,414,002 Cheng	adsingh				_	
99. 07/02/2002 6,414,002 Cheng						
	g et al.					
100. 07/02/2002 6,414,008 Hauel	l et al.					
101. 07/16/2002 6,420,405 Inada	et al.					
	et al.					
	ıra et al.	··				
104. 09/17/2002 6,451,832 Ries e	et al.					
105. 10/22/2002 6,468,996 Jeppe	esen et al.					
106. 10/22/2002 6,469,039 Hauel	l et al.					
107. 11/05/2002 6,476,023 Cirillo	o et al.					
108. 11/12/2002 6,479,524 Priepl	ke et al.					
109. 11/26/2002 6,486,188 Peder	sen et al.		1			
Ref. Date Document No. No.	Country	Class	Subclass	Translat YES	tion NO	
. 110. 07/17/1997 WO 97/25042 WIPC)					
111. 08/07/1997 WO 97/28137 WIPC)				,	
112. 02/12/1998 WO 98/05331 WIPC) .	-	-			
7 113. 12/23/1998 WO 98/57941 . WIPC)					
114. 12/09/1999 WO 99/62870 WIPC)					
EXAMINER:	DATE CONSIDERED:					
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with no	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in					

Form PTO-1449			Docket Number 421842000400	Applicati	on Number 10/627,	372		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Harrihar A. PERSHADSINGH					
	· . \							
NOV 2 4 20	1.45	se several sheets if r	necessary)		Filing Date July 24, 2003	Group Ar	t Unit Not Yet Assi	gned
P. C.	- J				Mailing Date November 21, 20	03		
RADEMEN		12/00/1000	WO 00/62071	Turn				
		12/09/1999	WO 99/62871	WIP	-			
- //	116.	12/09/1999	WO 99/62872	WIP				
	117.	07/27/2000	WO 00/27832	WIP				
7/	118.	01/04/2001	WO 01/00603	WIP				
	119.	02/22/2001	WO 01/12612 ·	WIP	-			
	120.	03/29/2001	WO 01/21602	WIP				
	121.	05/17/2001	WO 01/34094	WIP	0			
/ح.	122.	10/03/2002	WO 02/076177	WIP	0			
·	Ref. No.	Title			-			
-	123.	GenBank Accession No. J03258, "Cloning and Expression of Full-Length cDNA Encoding Human Vitamin D Receptor" created on January 14, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
-	124.	GenBank Accession No. L02932, "cDNA Cloning, Chromosomal Mapping, and Functional Characterization of the Juman Peroxisome Proliferator Activated Receptor" created on July 26, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
· -	125.	Member of S	GenBank Accession No. L13740, "Isolation and Characterization of Human TR3 Receptor: A Member of Steroid Receptor Superfamily" created on June 12, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
-	126.	GenBank Accession No. L14160, "The Development of Sequence-Tagged Sites for Human Chromosome 4" created on August 10, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
	127.	GenBank Accession No. L14611, "Identification of Nuclear Receptor mRNAs by RT-PCR Amplification of Conserved Zinc-Finger Motif Sequences" created on October 16, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
	128.	GenBank Accession No. L27586, "Human and Rat TR4 Orphan Receptors Specify a Subclass of the Steroid Receptor Superfamily" created on September 15, 1994, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
	129.	GenBank Accession No. L31785, "A New Orphan Member of the Nuclear Hormone Receptor Superfamily Closely Related to Rev-Erb" created on May 8, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
	130.	130. GenBank Accession No. L40904, "Isolation of the Human Peroxisome Proliferator Activated Receptor Gamma cDNA: Expression in Hematopoietic Cells and Chromosomal Mapping" created on December 26, 2001, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
EXAMIN	NER:				DATE CONSIDER	ED:		
					on conforms with MPEP 609. next communication to applica	_	the citation if n	ot in

Form PTC)-1449		Docket Number 421842000400	Application Number 10/627,372			
AVFOR	ITAMS	ON DISCLOSURE CITATION	Applicant				
	M	AN APPLICATION	Harrihar A. PE	RSHADSINGH			
NOV 242		se several sheets if necessary)	Filing Date July 24, 2003 Group Art Unit Not Yet Assigned				
RUI 242 名			Mailing Date November 21, 2003				
	av die						
MADEMI	131.	GenBank Accession No. M24748, "Ch Coexpressed with Other Thyroid Horn located at http://www.ncbi.nlm.nih.go	none Receptors in Several Tissue	es" created on May 9, 1995,			
	132.	GenBank Accession No. M24857, "A Third Human Retinoic Acid Receptor, hRAR-gamma" created on November 8, 1994, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	133.	GenBank Accession No. M24898, "Two erbA Homologs Encoding Proteins with Different T3 Binding Capacities are Transcribed from Opposite DNA Strands of the Same Genetic Locus" created on November 7, 1994, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	134.	GenBank Accession No. M26747, "Human Steroid Receptors and erbA Proto-Oncogene Products: Members of a New Superfamily of Enhancer Binding Proteins" created on June 11, 2002, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
ئ ــــــــــــــــــــــــــــــــــــ	135.	GenBank Accession No. M29960, "Molecular Cloning of New Human TR2 Receptors: A Class of Steroid Receptor with Multiple Ligand-Binding Domains" created on August 3, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
سو	136.	GenBank Accession No. M64497, "Regulation of the Apolipoprotein AI Gene by ARP-1, a Novel Member of the Steroid Receptor Superfamily" created on January 31, 1996, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
_	137.	GenBank Accession No. M81385, "Expression and Functional Analysisi of Liver Receptor Homologue-1 as a Potential Steroidogenic Factor in Rat Ovary" created on July 22, 2003, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	138.	GenBank Accession No. M84820, "Puwith which RAR or TR Heterodimerize 1995, located at http://www.ncbi.nlm	es to Bind Target Sequences Eff	iciently" created on January 9,			
•	139.	GenBank Accession No. S65876, "Cha Key Regulator of Steroid Hydroxylase http://www.ncbi.nlm.nih.gov > last vi	Gene Expression" created on M				
	140.	GenBank Accession No. S77482, "The Mouse Homolog of the Orphan Nuclear Receptor Tailless is Expressed in the Developing Forebrain" created on September 27, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	141.	GenBank Accession No. U10375, "Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-Activated Receptors" created on July 22, 1994, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	142.	GenBank Accession No. U11551, "A National Property of the Property of the Control					
	143.	GenBank Accession No. U12767, "The Isolation and Characterization of MINOR, a Novel Mitogen-Inducible Nuclear Orphan Receptor" created on June 17, 1996, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
EXAMI	NER:		DATE CONSIDERED:	DATE CONSIDERED:			
	• EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						

Form PTO	-1449		Docket Number 421842000400	Application Number 10/627,372			
NFOR	MATI	ON DISCLOSURE CITATION	Applicant				
10 m	WIN	AN APPLICATION	Harrihar A. PE	RSHADSINGH			
/ NUM 2 / 20		se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
_ NOV 2420 圣	m æl		Mailing Date November 21, 2003				
	10 C	· · · · · · · · · · · · · · · · · · ·	<u> </u>				
MADENIA	144.	GenBank Accession No. U14534, "Ub	iquitous Receptor: A Novel Rec	eptor That Modulates Gene			
		Activation by Retinoic Acid and Thyro http://www.ncbi.nlm.nih.gov last vis		on January 2, 1995, located at			
~	145.		cession No. U14666, "Cloning of a Novel Orphan Receptor (GCNF) Expressed During evelopment" created on March 23, 1996, located at http://www.ncbi.nlm.nih.gov last eptember 24, 2003.				
_	146.	GenBank Accession No. U16997, "ROR Gamma: The Third Member of ROR/RZR Orphan Receptor Subfamily that is Highly Expressed in Skeletal Muscle" created on April 4, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
7	147.	GenBank Accession No. U18374, "Identification of a Nuclear Receptor that is Activated by Farnesol Metabolites" created on June 21, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	148.	GenBank Accession No. U38480, "Characterization of Three RXR Genes that Mediate the Action of 9-cis Retinoic Acid" created on November 8, 1995, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	149.	GenBank Accession No. X06614, "A Transferable Silencing Domain is Present in the Thyroid Hormone Receptor, in the v-erbA Oncogene Product and in the Retinoic Acid Receptor" created on September 12, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
. •••	150.	GenBank Accession No. X12794, "Identification of Two Novel Members of erbA Superfamily by Molecular Cloning: The Gene Products of the Two are Highly Related to Each Other" created on June 25, 1997, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	151.	GenBank Accession No. X12795, "Ide Molecular Cloning: The Gene Products 25, 1997, located at http://www.ncbi.	s of the Two are Highly Related	to Each Other" created on June			
	152.	GenBank Accession No. X51416, "Identification of a New Class of Steroid Hormone Receptors" created on April 3, 1997, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	153.	GenBank Accession No. X51417, "Identification of a New Class of Steroid Hormone Receptors" created on February 10, 1999, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	154.	GenBank Accession No. X52773, "Nuclear Receptor That Identifies a Novel Retinoic Acid Response Pathway" created on September 12, 1993, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
	155.	GenBank Accession No. X75163, "A Novel Nuclear Receptor Superfamily Member in Xenopus That Associates with RXR, and Shares Extensive Sequence Similarity to the Mammalian Vitamin D3 Receptor" created on February 2, 1994, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
EXAMIN	IER:		DATE CONSIDERED:				
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						

Form PTO	-1449		Docket Number 421842000400	Application Number 10/627,372				
INFOR	MATI	ON DISCLOSURE CITATION	Applicant					
/ GTP		AN APPLICATION	Harrihar A. PE	RSHADSINGH				
NOV 2 4 20	n Stu	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned				
			Mailing Date November 21, 2003					
PADEMA	(dir							
ند.	156.	GenBank Accession No. X75918, "NO to the Steroid/Thyroid Hormone Recep http://www.ncbi.nlm.nih.gov last vis	otor NAK1/TR3" created on January	<u> </u>				
	157.	Hepatocyte Nuclear Factor 4 Indicate t	GenBank Accession No. X76930, "Clonign and Sequencing of cDNAs Encoding the Human Hepatocyte Nuclear Factor 4 Indicate the Presence of Two Isoforms in Human Liver" created on November 8, 1994, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
~	158.	Inappropriately Expressed in Human H	GenBank Accession No. Y00291, "A Novel Steroid Thyroid Hormone Receptor-Related Gene Inappropriately Expressed in Human Hepatocellular Carcinoma" created on January 14, 1991, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.					
مستعد	159.	GenBank Accession No. Z49826, "Human Hepatocyte Nuclear Factor 4 Isoforms Are Encoded by Distinct and Differentially Expressed Genes" created on September 6, 1999, located at http://www.ncbi.nlm.nih.gov last visited on September 24, 2003.						
4	160.	Adams, A.D. et al. (2003). "Amphipathic 3-Phenyl-7-propylbenzisoxazoles; Human PPaR γ , δ and α Agonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 13:931-935.						
	161.	Alberti, K.G.M.M. and Zimmet, P.Z. (1998). "Definition, Diagonisis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation," <i>Diabet. Med.</i> 15:539-553.						
4-	162.	Almansa, C. et al. (1996). "Diphenylpropionic Acids as New AT ₁ Selective Angiotensin II Antagonists," J. Med. Chem. 39:2197-2206.						
	163.	Almansa, C. et al. (1997). "Synthesis a AT ₁ Selective Angiotensin II Receptor <i>Chem.</i> 40:547-558.	· · · · · · · · · · · · · · · · · · ·	•				
	164.	American Diabetes Association (2002) 25(4):742-749.	. "The Prevention or Delay of T	ype 2 Diabetes," Diabetes Care				
	165.	American Medical Association. (2001) Cholesterol Education Program (NCEI High Blood Cholesterol in Adults (Adu	P) Expert Panel on Detection, Ev	valuation, and Treatment of				
	166.	American Medical Association. (2002). "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)," JAMA 288(23):2981-2997.						
	167.	Ashton, W.T. et al. (1994). "Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT ₁ Receptor Affinity and Enhanced AT ₂ Affinity," J. Med. Chem. 37:2808-2824.						
	168.	Atwal, K.S. et al. (1992). "Dihydropyrimidine Angiotensin II Receptor Antagonists," J. Med. Chem. 35:4751-4763.						
EXAMI	VER:		DATE CONSIDERED:					
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372			
INFORMAT	TION DISCLOSURE CITATION	Applicant Harrihar A. PERSHADSINGH				
	N AN APPLICATION	Harrinar A.	PERSHADSINGH			
NOV 2 4 2003	(Use several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
	<u> </u>	Mailing Date November 21, 2003				
MADEMIAN 169						
169.	Bernhart, C.A. et al. (1993). "A New a AT ₁ Angiotensin II Receptor Antagon		•			
170.	Bernobich, E. et al. (2002). "The Role Therapeutic Implications," <i>Drugs</i> 62(9)	ole of the Angiotensin System in Cardiac Glucose Homeostasis: 2(9):1295-1314.				
171.	Blankley, C.J. et al. (1991). "Synthesi Non-Peptide Angiotensin II Receptor <i>Chem.</i> 34:3248-3260.		•			
172.	Brasier, A.R. et al. (2000). "Angiotensin II Induces Gene Transcription Through Cell-Type-Dependent Effects on the Nuclear Factor-κB (NF-κB) Transcription Factor," Mol. Cell. Biochem. 212:155-169.					
173.	Brooks, D.A. et al. (2001). "Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4 yl)ethoxy]phenoxy}propionic Acids: A New Class of Dual PPARα/γ Agonists," J. Med. Chem. 44:2061-2064.					
174.	Bühlmayer, P. et al. (1991). "Nonpeptidic Angiotensin II Antagonists: Synthesis and in Vitro Activity of a Series of Novel Naphthalene and Tetrahydronaphthalene Derivatives," <i>J. Med. Chem.</i> 34:3105-3114.					
175.	Carini, D.J. et al. (1991). "Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)Imidazoles as Potent, Orally Active Antihypertensives," J. Med. Chem. 34:2525-2547.					
176.	Cronet, P. et al. (2001). "Structure of 242; Ligand Selectivity and Agonist A	•	•			
177.	Dahlöf, B. et al. (2002). "Cardiovascu Endpoint Reduction in Hypertension S Lancet 359:995-1003.	•				
178.	Danforth, E. Jr. (2000). "Failure of Ac Nat. Genet. 26:13.	dipocyte Differentiation Causes	Type II Diabetes Mellitus?"			
179.	De, B. et al. (1992). "Discovery of a N Antagonists," J. Med. Chem. 35:3714	•	Ion-Peptide Angiotensin II			
180.	Dhanoa, D.S. et al. (1993). "(Dipropy Angiotensin II Receptor Antagonists,"					
181.	Easthope, S.E. and Jarvis, B. (2002). "Candesartan Cilexetil: An Update of its Use in Essential Hypertension," <i>Drugs</i> 62(8):1253-1287.					
182.	2. Ellingboe, J.W. et al. (1998). "Metabolites of the Angiotensin II Antagonist Tasosartan: The Importance of a Second Acidic Group," J. Med. Chem. 41:4251-4260.					
		•				
EXAMINER:		DATE CONSIDERED:				
	itial if citation considered, whether or not the citat not considered. Include a copy of this form with		a line through the citation if not in			

Form PTO-1449			Docket Number 421842000400	Application Number 10/627,372			
CINEOR	MATI N	ON DISCLOSURE CITATION AN APPLICATION	Applicant Harrihar A. PERSHADSINGH				
NOV 2 4 2003	E (U	se several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
MINA T 4 THOS	# H		Mailing Date November 21, 2003				
40							
RADEMAN	183.	Epstein, M. (2002). "Angiotensin II Re II Receptor Antagonists Epstein, M. and PA. pp. 257-261.	•				
	184.	Ford, E.S. et al. (2002). "Prevalence of the Third National Health and Nutritio	•				
	185.	Galvin, P. et al. (1992). "A Simple Me From an Intravenous Glucose Tolerand	•	•			
	186.	Groff, J.L. et al. (1993). "Simplified Et Clin. Chem. 39(3):400-404.	nzymatic Assay of Angiotensin	-Converting Enzyme in Serum,"			
	187.	7. Hansson, L. et al. (1999). "Effect of Angiotensin-Converting-Enzyme Inhibition Compared wi Conventional Therapy on Cardiovascular Morbidity and Mortality in Hypertension: The Capto Prevention Project (CAPPP) Randomised Trial," <i>The Lancet</i> 353:611-616.					
	188.	Henke, B.R. et al. (1998). "N-(2-Benzoylphenyl)-L-Tyrosine PPARγ Agonists. 1. Discovery of Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents," J. Med. Chem. 41:5 5036.					
	189.	Henriksen, E.J. et al. (2001). "Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats," <i>Hypertension</i> 38:884-890.					
	190.	Horiuchi, M. et al. (2003). "Fluvastatin Enhances the Inhibitory Effects of a Selective Angiotensin II Type 1 Receptor Blocker, Valsartan, on Vascular Neointimal Formation," Circulation 107:106-112.					
	191.	Janke, J. et al. (2002). "Mature Adipoo Via Angiotensin Type 1 Receptors," D		ntion of Human Preadipocytes			
	192.	Katsuki, A. et al. (2001). "Homeostasi Resistance During Follow-up of Patier					
	193.	Kubo, K. et al. (1993). "Nonpeptide A Activity of Benzimidazoles," J. Med. (•	ists. Synthesis and Biological			
	194.	Laaksonen, D.E. et al. (2002). "Metabe Application and Validation of Recently Prospective Cohort Study," <i>American</i>	y Suggested Definitions of the l	Metabolic Syndrome in a			
	195.	Le Bourdonnec, B. et al. (2000). "Synt 5-diones as AT ₁ Receptor Antagonists		,			
	196.	Le Bourdonnec, B. et al. (2002). "Comparison of 3D Structures and AT ₁ Binding Properties of Pyrazolidine-3,5-diones and Tetrahydropyridazine-3,6-diones with Parent Antihypertensive Drug Irbesartan," J. Med. Chem. 45:4794-4798.					
	197.	Lin, H.S. et al. (1992). "Nonpeptide A Computational Chemistry of N-[[4-(2]] Derivatives and Their In Vitro Activity	H-Tetrazol-5-yl)-1-Cycloalken-	1-yl]Phenyl]Methyl]Imidazole			
EXAMIN	IER:		DATE CONSIDERED:				
		al if citation considered, whether or not the citatiot considered. Include a copy of this form with r		line through the citation if not in			
PTO/SB/ 08 (2 pa- 820933	2-92)		Patent and Trademark Office; U	J.S. DEPARTMENT OF COMMERCE			

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Harrihar A. PERSHADSINGH				
NOV 2 4 2003 (Use several sheets if necessary)		Filing Date July 24, 2003	Group Art Unit Not Yet Assigned			
		Mailing Date November 21, 2003				
TAUENIA 198.						
198.	Maillard, M.P. et al. (2002). "Pharmacodynamics and Drug Action: Comparative Angiotensin II Receptor Blockade in Healthy Volunteers: The Importance of Dosing," <i>Clin. Pharmacol. Ther.</i> 71(1):68-76.					
199.		Non-Peptide Angiotensin II Receptor Antagonists: Synthesis and vel 4,5-Dihydro-4-oxo-3 <i>H</i> -imidazo(4,5- <i>c</i>)pyridine Derivatives,"				
200.	· · · · · · · · · · · · · · · · · · ·	1. (2003). "The Natural History of Progression From Normal Glucose Tolerance to s in the Baltimore Longitudinal Study of Aging," <i>Diabetes</i> 52:1475-1484				
201.	Miyajima, A. et al. (2002). "Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogensis," Cancer Res. 62:4176-4179.					
202.	Miyazaki, M. et al. (1999). "Angiotensin II Type I Receptor Antagonist, TCV-116, Prevents Neointima Formation in Injured Arteries in the Dog," <i>Jpn. J. Pharmacol.</i> 79:455-460.					
203.	Nelson, K.A. et al. (1994). "The Cancer Anorexia-Cachexia Syndrome," <i>Journal of Clinical Oncology</i> 12(1):213-225.					
204.	Norman, M.H. et al. (1995). "4-(Heteroarylthio)-2-biphenylyltetrazoles as Nonpeptide Angiotensin II Antagonists," <i>J. Med. Chem.</i> 38:4670-4778.					
205.	Phillips, M.I. and Kagiyama, S. (2002). "Angiotensin II As A Pro-Inflammatory Mediator," Curr. Opin. Investig. Drugs 3(4):569-577.					
206.	Sasaki, K. et al. (2002). "Evidence for the Importance of Angiotensin II Type 1 Receptor in Ischemia-Induced Angiogenesis," J. Clin. Invest. 109:603-611.					
207.	Schmidt, B. and Schieffer, B. (2003). "Angiotensin II AT1 Receptor Antagonists. Clinical Implications of Active Metabolites," <i>J. Med. Chem.</i> 46(12):2261-2270.					
208.	Sharma, A.M. et al. (2002). "Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells," <i>Hypertension</i> 40:609-611.					
209.	Shiuchi, T. et al. (2002). "ACE Inhibitor Improves Insulin Resistance in Diabetic Mouse via Bradykinin and NO," <i>Hypertension</i> 40:329-334.					
210.	Silvestre, J.S. et al. (2002). "Antiangiogenic Effect of Angiotensin II Type 2 Receptor in Ischemia-Induced Angiogenesis in Mice Hindlimb," Circ. Res. 90:1072-1079.					
211.	Smith, K.L. and Tisdale, M.J. (1993). "Mechanism of Muscle Protein Degradation in Cancer Cachexia," <i>British Journal of Cancer</i> 68:314-318.					
212.	Tamarat, R. et al. (2002). "Angiotensin II Angiogenic Effect in Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways," Lab. Invest. 82(6):747-756.					
213.	Tanaka, Y. et al. (1989). "Antitumor Activity of Indomethacin in Mice Bearing Advanced Colon 26 Carcinoma Compared with Those with Early Transplants," <i>Cancer Research</i> 49:5935-5939.					
EXAMINER:		DATE CONSIDERED:				
	ial if citation considered, whether or not the citat not considered. Include a copy of this form with		a line through the citation if not in			

Form PTO-1449		Docket Number 421842000400	Application Number 10/627,372		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Harrihar A. PERSHADSINGH			
NOV 2 4 2003 &	(Use several sheets if necessary)	Filing Date July 24, 2003	Group Art Unit Not Yet Assigned		
		Mailing Date November 21, 2003			
PADEMARK					
214.	•	Seuscher, A.U. and Weidmann, P.U. (1997). "Requirements for Antihypertensive Therapy in Diabetic Patients: Metabolic Aspects," <i>Journal of Hypertension</i> 15(Supp. 2):S67-S75.			
215.	Tham, D.M. et al. (2002). "Angiotensin II Is Associated With Activation of NF-kB-Mediated Genes and Downregulation of PPARs," <i>Physiol. Genomics</i> 11:21-30.				
216.	Tomiyama, H. et al. (1994). "Kinins Contribute to the Improvement of Insulin Sensitivity During Treatment with Angiotensin Converting Enzyme Inhibitor," <i>Hypertension</i> 23:450-455.				
217.	Wang, N. et al. (2002). "Constitutive Activation of Peroxisome Proliferator-Activated Receptor-γ Suppresses Pro-Inflammatory Adhesion Molecules in Human Vascular Endothelial Cells," <i>J. Biol. Chem.</i> 277(37):34176-34181.				
218.	Yusuf, S. et al. (2001). "Ramipril and the Development of Diabetes," JAMA 286:1882-1885.				
219.	Zimmet, P. et al. (2001). "Global and Societal Implications of the Diabetes Epidemic," <i>Nature</i> 414:782-787.				

EX.	A N	IIN	FR	٠

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)